JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients

NCT05800535 | Recruiting

• 2 other identifiers: 81369HCL23_0177
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital). JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers. This study is non-interventional, it uses research on data that is already collected as part of conventional care, during the JUMP evaluation day. This study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received. Our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the JUMP program.

Conditions

Cancer; Sarcopenia

Keywords

Post cancer; Chemobrain; Sarcopenia; Medical evaluation

Outcome Measures

Primary Outcomes (1)

• Prevalence of patients with physical and neurocognitive impairment

  Number of patients whose medical assessments show altered physical, cognitive or anxiety/dpression activity compared to the measurement in the general population

  at least 1 year later after chemical treatments

Study Arms (1)

JUMP Cohort

This study concerns adults with cancer treated with chemotherapy, radiotherapy, hormonal therapy or immunotherapy, in remission or cured. Patients took part in the dedicated post-cancer assessment day.

Drug: Study of the adverse effects of long-term oncological treatments; Behavioral: Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients

Interventions

Study of the adverse effects of long-term oncological treatments DRUG

Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

JUMP Cohort

Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients BEHAVIORAL

Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

JUMP Cohort

Eligibility Criteria

• Age: 18 Years - 74 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients who have been treated for cancer and who have completed the post-cancer assessment day

You may qualify if:

• Age : 18 to 74 years
• localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy
• patient who benefited from the post-cancer assessment day-

You may not qualify if:

• Under 18years
• Over 74 years
• Patient who did not received any chemical treatment
• Patient who do not wish to participate

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud

Pierre-Bénite, 69310, France

RECRUITING

MeSH Terms

Conditions

Neoplasms; Sarcopenia; Chemotherapy-Related Cognitive Impairment

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Drug-Related Side Effects and Adverse Reactions; Chemically-Induced Disorders; Cognitive Dysfunction; Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Central Study Contacts

Cyrille CONFAVREUX, MD

CONTACT

+334 78 86 12 31; Cyrille.confavreux@chu-lyon.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 24, 2023
• First Posted: April 5, 2023
• Study Start: February 10, 2025
• Primary Completion (Estimated): February 10, 2029
• Study Completion (Estimated): February 10, 2029
• Last Updated: November 21, 2025

Record last verified: 2025-11

Locations

FR (1)